Statintherapy in the primary and the secondary prevention of ischaemic cerebrovascular diseases

Fehér, Andrea; Pusch, Gabriella; Koltai, Katalin; Tibold, Antal; Gasztonyi, Beáta; Szekeres, L.; Fehér, Gergely

doi:10.1016/j.ijcard.2010.08.012

Cited by 13 publications

(17 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Lipid parameters should be monitorized, there are class effects in the lipid lowering potency of different drugs (1). As previously shown, worsening lipid profile has been associated with unfavourable outcome.…”

Section: Final Conclusionmentioning

confidence: 99%

“…Cardiovascular disease is the leading cause of death and disability in Europe [1]. Several large, population-based trials and their metaanalyses have shown the beneficial effects of statins in reducing mortality and cardiovascular morbidity both primary and secondary prevention [1,2].…”

Section: Introductionmentioning

confidence: 99%

“…Several large, population-based trials and their metaanalyses have shown the beneficial effects of statins in reducing mortality and cardiovascular morbidity both primary and secondary prevention [1,2]. Statins have been associated with a variety of pleiotropic effects, including atherosclerotic plaque stabilization, decreased inflammation, improvement in endothelial function, and altered thrombogenicity [1,2].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Generic Statins in Cardiovascular Medicine

Fehér¹,

Pusch²,

Harang³

2011

JBB

Self Cite

View full text Add to dashboard Cite

Cardiovascular disease is the leading cause of death and disability in Europe. Several large, population-based trials and their meta-analyses have shown the beneficial effects of statins in reducing mortality and cardiovascular morbidity both primary and secondary prevention. Use of generic drugs, which are bioequivalent to brand-name drugs, can help contain prescription drug spending. However, there is concern among patients and physicians that brandname drugs may be clinically superior to generic drugs. The aim of our study was to review the efficacy of generic statin therapy in both primary and secondary vascular prevention.Treatment with generic statins seem to be safe and quite effective. Lipid parameters should be monitorized, there are class effects in the lipid lowering potency of different drugs. Based on comparism trials, worsening lipid profile was associated with unfavourable outcome. From an economic point of view, society could gain a lot from substituting statin therapy, especially from therapeutic substitution. Moreover, prescribing generic or preferred medications within a therapeutic class seemed to be associated with improvements in adherence to therapy.

show abstract

Section: Final Conclusionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Generic Statins in Cardiovascular Medicine

Fehér¹,

Pusch²,

Harang³

2011

JBB

Self Cite

View full text Add to dashboard Cite

show abstract

“…Magyarországon a cardioés cerebrovascularis betegségek előfordulási gyakorisága a nemzetközi adatokhoz viszonyítva is nagy [5]. Tekintettel arra, hogy elsősorban a hypertonia áll ezek hátteré-ben, rendkívül fontos a tenzió adekvát beállítása, amelylyel a vascularis események rizikója jelentősen csökkenthető, különös tekintettel e betegségek magas mortalitására, az akut esemény lezajlása után visszamaradó életminőség-és munkaképesség-csökkenésre [5,6].…”

Section: ] (2 Táblázat)unclassified

Role of antihypertensive drugs in the treatment of migraine

Fehér

Pusch

2015

Orvosi Hetilap

Self Cite

View full text Add to dashboard Cite

A migrén kezelési stratégiája a fejfájás gyakoriságától és súlyosságától, továbbá az egyidejűleg fennálló egyéb betegsé-gektől függ. Számos gyógyszert hoztak forgalomba kimondottan a migrén kezelésére, azonban primeren más betegség kezelésére alkalmas szer is hasznos lehet. A szerzők irodalmi kutatáson alapuló munkájának célja a vérnyo-máscsökkentő szerek (béta-blokkoló, kalciumcsatorna-blokkoló, angiotenzinkonvertálóenzim-gátló, angiotenzinreceptor-blokkoló és egyéb szerek) migrénprofi laxisban való szerepének és a kedvező hatást alátámasztó bizonyítékok áttekintése. Vizsgálták továbbá e szerek egyéb hatásait (cardiovascularis hatás, béta-blokkolók szívbetegség hiányában való adásának potenciálisan hátrányos hatásai, esetleges extrapyramidalis mellékhatások kalciumcsatorna-blokkolók alkalmazásakor, angiotenzinkonvertálóenzim-gátló és angiotenzinreceptor-blokkoló szerek egyéb additív hatásai). A rendelkezésre álló bizonyítékok alapján strukturális szívbetegség hiányában migrén és hypertonia együttes fennállása esetén angiotenzinkonvertálóenzim-gátló (elsősorban lisinopril) vagy angiotenzinreceptor-blokkoló (elsősorban candesartan) kezelés ajánlott, szívbetegség esetén javasolt csak béta-blokkoló hosszú távú adása. Orv. Hetil., 2015, 156(5), 179-185. Kulcsszavak: vérnyomáscsökkentő gyógyszer, migrén, kezelés, megelőzés Role of antihypertensive drugs in the treatment of migraineThe treatment of migraine depends on the frequency, severity and concomitant diseases. There are several specifi c drugs developed for migraine prevention in addition to the additive antimigraine effects of some other non-specifi c drugs. The aim of this literature-based review is to summarize the possible antimigraine properties of different antihypertensive agents (beta-blockers, calcium channel blockers, angiotensin converting enzyme inhibitors, angiotensin receptor blockers, etc.) focusing on the possible side effects (avoidance of beta blockers in the absence of heart disease, possible antiparkinson effect of calcium channel blockers, additive effect of drugs modifying the renin-angiotensin system activity, etc.). Current evidence supports the use of angiotensin converting enzyme inhibitors (mainly lisinopril) and angiotensin receptor blockers (mainly candesartan) for long-term migraine prevention and blood pressure control. Long-term beta-blocker treatment should be avoided in the absence of ischemic heart disease due to possible unfavourable cardiovascular effects. Keywords: antihypertensive drugs, migraine, treatment, preventionFehér, G., Pusch, G. [Role of antihypertensive drugs in the treatment of migraine]. Orv. Hetil., 2015, 156(5), 179-185. (Beérkezett: 2014 elfogadva: 2014. november 6.) A fejfájás (és ezen belül a migrén) az orvosok által talán leggyakrabban látott neurológiai kórkép. Nagy epidemiológiai vizsgálatok szerint a migrén a lakosság 10-12%-át érintheti: Magyarországon legalább 1 millió migrénessel kell számolnunk [1]. A migrén tehertétele jelentős, ez megnyilvánul mind a beteg közérzetében (életminőségi mutató...

show abstract

“…1) Stroke is the third leading cause of death worldwide, and it results in the permanently disabled of 15 to 30% of patients and accounts for socioeconomic burden due to a rise in the aging population. [2][3][4] A thrombus occluding a brain artery is the leading mechanism underlying ischemic stroke, 5) which accounts for approximately 70-85% of all stroke 6) and no effective therapies are available. 7) The safe and effective drugs have been the research focus of ischemic stroke therapy.…”

mentioning

confidence: 99%

The Permeability of Puerarin Loaded Poly(butylcyanoacrylate) Nanoparticles Coated with Polysorbate 80 on the Blood–Brain Barrier and Its Protective Effect against Cerebral Ischemia/Reperfusion Injury

Zhao

Liu

et al. 2013

Biological & Pharmaceutical Bulletin

View full text Add to dashboard Cite

Puerarin (PUE) is a good candidate for treating stroke, but its low concentration in brain after administration limits its curative efficacy. The aim of the present work was to design and characterize PUE loaded poly(butylcyanoacrylate) nanoparticles (PBCN) coated with polysorbate 80 (Ps 80), and to evaluate the effect of PBCN on the permeability of PUE across the blood-brain barrier (BBB) and the effect of PUE loaded PBCN on the cerebral ischemia/reperfusion injury. PUE loaded PBCN were successfully prepared by anionic polymerization method with the mean particle size of 201.2 nm and the zeta potential of −7.72 mV. The in vitro release behavior of PUE from the nanoparticles showed a biphasic profile manner with an initial burst release followed by a sustained release. The results of pharmacokinetic and biodistribution to brain performed in mice after intravenous administration showed that the drug concentrations in blood and brain for PUE loaded PBCN were both greater than these for the free drug. Moreover, compared with free drug, the vein injection of PUE loaded PBCN exerted the better neuroprotective effect in rats with focal cerebral ischemic injury via significantly decreasing neurological deficit scores, increasing body weight, lowing brain water content, and reducing the infarct volume. The results indicated that this preparation may reduce the total dose required for the stroke therapy with concurrent reduction in dose related toxicity. All these findings suggest that PBCN could enhance the transport of PUE to brain and have a potential as a neuroprotective agent in the focal cerebral ischemic injury.

show abstract

Statintherapy in the primary and the secondary prevention of ischaemic cerebrovascular diseases

Cited by 13 publications

References 48 publications

Generic Statins in Cardiovascular Medicine

Generic Statins in Cardiovascular Medicine

Role of antihypertensive drugs in the treatment of migraine

The Permeability of Puerarin Loaded Poly(butylcyanoacrylate) Nanoparticles Coated with Polysorbate 80 on the Blood–Brain Barrier and Its Protective Effect against Cerebral Ischemia/Reperfusion Injury

Contact Info

Product

Resources

About